1. China Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
ClouDr Group Limited

ClouDr Group Limited

0.05
EUR
+0.00
(-0.98%)
65.89MMarket Cap
Mar 25Next Earn
ClouDr Group Limited
GETTEX:H3L
(Gettex)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.92
1.48
3.09
9.95
6.82
6.01
2.66
- -
Revenue per Share
-0.98
-5.05
-7.29
-5.62
-0.6
-0.89
-1.52
- -
Basic EPS, GAAP
-0.64
-0.84
-1.33
-2.7
-0.49
-0.39
-0.14
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.46
-5.73
-12.16
3.15
3.11
2.48
0.85
0.85
Book Value per Share
-1.51
-5.95
-12.48
2.45
2.54
2.01
0.55
0.55
Tangible Book Value per Share
568
568
568
300
541
580
610
620
Basic Weighted Avg Shares
524
839
1,757
2,988
3,691
3,488
1,623
- -
Sales/Revenue/Turnover
-35.35
-100.02
-40.31
-18.94
-8.61
-6.68
-17.49
- -
Operating Margin (%)
9
35
87
102
108
102
71
- -
Depreciation Expense
-557
-2,867
-4,139
-1,689
-323
-516
-924
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-106.28
-341.66
-235.6
-56.52
-8.75
-14.8
-56.93
- -
Profit Margin (%)
-906
-3,535
-7,362
1,364
1,202
943
32
32
Working Capital
2
2
5
20
33
23
18
18
LT Debt
-872
-3,393
-7,155
1,881
1,765
1,433
487
487
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-17.58
-31.5
-92.31
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
344
304
270
LT Borrowings
9
11
9
LT Finance Leases
13
15
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
587
646
646
Market Capitalization
593
534
541

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2,297
1,539
1,177
Cash, Cash Equivalents & STI
532
445
411
Accounts Receivable, Net
683
477
337
Inventories
169
176
162
Total Current Liabilities
1,353
1,274
1,145
Payables & Accruals
- -
- -
- -
ST Debt
344
304
270
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-21.28%
-65.98%
Free Cash Flow
- -
-15.9%
-62.4%
Net Income, GAAP
- -
8.62%
78.96%
Sales/Revenue/Turnover
- -
28.8%
-53.47%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3,691
2024
- -
- -
3,488
2025
- -
- -
1,623

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.6
2024
- -
- -
-0.89
2025
- -
- -
-1.52

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
ClouDr Group Limited, an investment holding company founded in 2014 and headquartered in Hangzhou, China, provides medical supplies and software-as-a-service (SaaS) solutions to hospitals and pharmacies; digital marketing services to pharmaceutical companies; and online consultations and prescriptions for chronic condition management patients primarily in China. The company's integrated offerings encompass in-hospital solutions featuring AI-driven hospital SaaS for diagnosis, treatment, and doctor education, proprietary artificial intelligence of things (AIoT) devices, sales of medical devices and consumables, and digital marketing via its SaaS network; pharmacy solutions including pharmacy SaaS for real-time in-store consultations, prescriptions, inventory management, and sales of chronic condition-related drugs based on data insights; and individual chronic condition management solutions connecting over 100,000 registered doctors and 29.7 million registered users through omni-channel platforms like ClouDr Mini Program, Dr. ClouDr app, and three internet hospitals for out-of-hospital monitoring, premium membership services, insurance brokerage, and advertisement agency services, with operations focused on cardiovascular diseases such as hypertension and diabetes. Recent developments include reporting earnings for the full year ended December 31, 2024, issuing approximately $4.5 million in convertible bonds in March 2025, achieving its first quarterly profit in Q4 2023 driven by growth in in-hospital and pharmacy segments, entering a non-legally binding strategic cooperation agreement with Hong Kong Magicure Medical Co., Ltd. in 2023 for cross-border access to innovative oncology and rare disease medicines, and a service cooperation agreement with JD Health International.